Your browser doesn't support javascript.
loading
BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate.
Huang, Xinjian; Shi, Dongni; Zou, Xuxiazi; Wu, Xuxia; Huang, Shumei; Kong, Lingzhi; Yang, Muwen; Xiao, Yunyun; Chen, Boyu; Chen, Xiangfu; Ouyang, Ying; Song, Libing; Jian, Yunting; Lin, Chuyong.
Affiliation
  • Huang X; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Shi D; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Zou X; Department of Breast Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Wu X; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Huang S; Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
  • Kong L; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Yang M; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Xiao Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Chen B; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Chen X; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Ouyang Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Song L; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Jian Y; Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences; Guangzhou Institute of Oncology, Tumor Hospital, Guangzhou Medical University, 511436, Guangzhou, China.
  • Lin C; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Theranostics ; 13(1): 339-354, 2023.
Article in En | MEDLINE | ID: mdl-36593950
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Tumor Suppressor Protein p53 / Molecular Chaperones / Drug Resistance, Neoplasm Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Theranostics Year: 2023 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Tumor Suppressor Protein p53 / Molecular Chaperones / Drug Resistance, Neoplasm Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Theranostics Year: 2023 Type: Article Affiliation country: China